AGA Releases Position Statement on Management of Hepatitis C

[Guest guest]

Practice Guideline Briefs

AGA Releases Position Statement on Management of Hepatitis C

The demand to manage hepatitis C virus (HCV) infection has increased over

the past decade, and current predictions are that HCV-associated morbidity

and mortality rates will escalate in the next 20 years. The American

Gastroenterological Association (AGA) has released a review and position

statement on the management of HCV infection. The report was published in

the January 2006 issue of Gastroenterology.

Routine screening is not necessary for asymptomatic adults with a low

probability of infection. Persons in high-risk groups (e.g., injection drug

users, immigrants from countries with high rates of infection) should be

tested for HCV.

Potential candidates for antiviral therapy include patients who have a

reactive enzyme immunoassay for antibody to HCV and those with HCV RNA or

compensated liver disease. Elevated alanine transaminase and aspartate

transaminase levels are not required for therapy.

Preferred therapy for previously untreated patients with HCV infection

consists of a weekly subcutaneous injection of pegylated interferon alfa and

oral ribavirin (Rebetol) taken daily. Pegylated interferon is considered the

best treatment for patients with indications for antiviral therapy but who

have contraindications to ribavirin. Two pegylated interferon alfa

preparations are available: pegylated interferon alfa-2a (Pegasys), which is

administered at a fixed 180-mcg dose, and pegylated interferon alfa-2b

(PEG-Intron), which is administered at a dose of 1.5 mcg per kg.

HCV RNA levels should be monitored using the same quantitative amplification

assay at baseline and 12 weeks. An early virologic response (i.e., a

reduction in HCV RNA levels of at least 2-log10 within the first 12 weeks of

therapy) is a valuable clinical milestone. Without the early virologic

response, the chance of sustained virologic response is 3 percent or less.

During therapy, clinical and virologic monitoring should be performed at

intervals of once per month to once every three months.

Treatment recommendations may vary for other patients, including those with

cirrhosis, acute hepatitis C, hematologic disorders, end-stage renal

disease, extrahepatic disease, and human immunodeficiency virus, as well as

patients who are injection-drug or alcohol users, have had a liver

transplant, or have relapsed or did not respond to previous HCV therapy.

Treatment is not recommended for patients younger than three years.

LISA GRAHAM

http://www.aafp.org/afp/20060901/practice.html#p3

_________________________________________________________________

All-in-one security and maintenance for your PC. Get a free 90-day trial!

http://www.windowsonecare.com/trial.aspx?sc_cid=msn_hotmail